The DOI matches its Crossref record, with a small difference in title or year; 26 of the 26 references it cites were found in a registry or an index.
Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade
Abstract
BACKGROUND: Immune checkpoint inhibitors are poised to revolutionize the management of a growing number of malignancies. Unfortunately, the management of steroid-refractory immune mediated adverse events is based on a paucity of randomized data and limited to single center experiences. Our initial experience with the IL-6 receptor antagonist tocilizumab showed clinical improvement in a wide variety of irAEs. As a result, we adopted the use of tocilizumab for the management of steroid refractory irAEs. METHODS: The character and clinical course of irAEs were abstracted from the medical record and analyzed. The dose of tocilizumab was 4 mg/kg given IV over one hour. C-reactive protein was drawn at first nivolumab infusion and at q two weeks (and with irAEs) thereafter. Clinical improvement was defined as either: documentation of resolution of symptoms or hospital discharge within seven days. RESULTS: Of the initial 87 patients that were treated with nivolumab, 34 required tocilizumab (39.1%). All patients were on corticosteroids. The majority (88.2%) were lung cancer patients. The index grade 3/4 irAE was pneumonitis in 35.3%, serum sickness/SIRS in 35.3%, cerebritis in 14.7% and one case each of hypophysitis, colitis, pancreatitis, hepatitis and immune mediated coagulopathy. Median time between first nivolumab and initiation of tocilizumab was 76 days (range 1-429). There was a statistically significant increase in C-reactive protein from a median of 23 mg/L (range 0.1-238.5) at baseline to 109.3 mg/L (21.5-350.4) at the time of index irAE, followed by a decrease to 19.2 mg/L (0.25-149) after tocilizumab ( p < 0.00001). Clinical improvement was noted in 27/34 patients (79.4%). Some patients (52.9%) required a single dose, while 38.2% required two, 8.8% required three and 1 patient required four doses. Twenty-seven doses were given in the inpatient setting (49.1%). Median time to discharge was four days (range 1-27). Seventy-four percent of patients were discharged home. For the 53 doses of tocilizumab that were delivered when infliximab was an option, there was a cost savings of $141,048.72 (WAC) during the 18 month study period. CONCLUSIONS: Tocilizumab may be a therapeutic option for the management of steroid refractory irAEs secondary to immune checkpoint blockade. However, randomized trials are needed to better elucidate the relative efficacy and safety of these agents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, it was demonstrated that TCZ may be used as a second-line therapy for irAEs and for steroid-refractory irAEs; clinical improvement was observed in 79.4% of patients, with 52.9% of patients requiring only a single dose for a symptomatic response.59”
From Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy (2020) · cites this paper as [59]
Citations
Cites
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
The pro- and anti-inflammatory properties of the cytokine interleukin-6
Scheller, J., Chalaris, A., Schmidt-Arras, D., & Rose-John, S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.034 · Cited by 3,212
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
Chung, C. H., Mirakhur, B., Chan, E., Le, Q.-T., Berlin, J., Morse, M., Murphy, B. A., Satinover, S. M., Hosen, J., Mauro, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074943 · Cited by 1,521
Toxicities of chimeric antigen receptor T cells: recognition and management
Brudno, J. N., & Kochenderfer, J. N. (2016) · Blood · doi:10.1182/blood-2016-04-703751 · Cited by 1,283
Research works printed but not linked: 4
- Haratani K, JAMA Oncol
- Shoushtari AN, JAMA Oncol
- 10.1093/annonc/mdv623 · DOI · Paper page
- Kim N, 2015, Oncology Letters, 9
Cited by
Sorted by citations
Items 101–200 of 330
A Review of Immune-Mediated Adverse Events in Melanoma
Kennedy, L. B., & Salama, A. K. S. (2019) · Oncology and Therapy · doi:10.1007/s40487-019-0096-8 · Cited by 41
Implications of metabolism-driven myeloid dysfunctions in cancer therapy
Strauss, L., Guarneri, V., Gennari, A., & Sica, A. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00556-w · Cited by 39
Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition
Naqash, A. R., Appah, E. O., Yang, L. V., Muzaffar, M., Marie, M. A., McCallen, J., Macherla, S., Liles, D., & Walker, P. R. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0648-3 · Cited by 38
Self-citationPïcca, A., Valyraki, N. E., Birzu, C., Kramkimel, N., Hermine, O., Zahr, N., Berzero, G., & Psimaras, D. (2021) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000001073 · Cited by 40
Rapoport, B. L., Shannon, V. R., Cooksley, T., Johnson, D. B., Anderson, L., Blidner, A. G., Tintinger, G. R., & Anderson, R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.743582 · Cited by 39
Dimitriou, F., Cheng, P. F., Saltari, A., Schaper‐Gerhardt, K., Staeger, R., Haunerdinger, V., Sella, F., Tastanova, A., Urban, C., Dettwiler, S., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00810-4 · Cited by 41
Infliximab for treatment-refractory transverse myelitis following immune therapy and radiation
Chang, V. A., Simpson, D. R., Daniels, G. A., & Piccioni, D. E. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0471-2 · Cited by 37
Facts and Hopes in Prediction, Diagnosis, and Treatment of Immune-Related Adverse Events
Smithy, J. W., Faleck, D. M., & Postow, M. A. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1240 · Cited by 35
Tofacitinib for treatment in immune-mediated myocarditis: The first reported cases
Liu, Y., & Jiang, L. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220947141 · Cited by 35
Dimitriou, F., Staeger, R., Ak, M., Maissen, M., Kudura, K., Barysch, M. J., Levesque, M. P., Cheng, P. F., Dummer, R., & Mangana, J. (2021) · Cancers · doi:10.3390/cancers13122931 · Cited by 33
Immune Checkpoint Inhibitor Myopathy
Beecher, G., Pinal‐Fernandez, I., Mammen, A. L., & Liewluck, T. (2024) · Neurology · doi:10.1212/wnl.0000000000210031 · Cited by 35
Amigues, I., Pearlman, A. H., Patel, A. M., Reid, P. D., Robinson, P. C., Sinha, R. R., Kim, A. H. J., Youngstein, T., Jayatilleke, A., & Konig, M. F. (2020) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1847084 · Cited by 33
Ielpo, S., Barberini, F., Moghaddam, F. D., Pesce, S., Cencioni, C., Spallotta, F., Ninno, A. D., Businaro, L., Marcenaro, E., Bei, R., et al. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102843 · Cited by 34
Future perspective: biologic agents in patients with severe COVID-19
Yalçın, A. D., & Yalçın, A. N. (2020) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2020.1818770 · Cited by 33
Immune checkpoint inhibitor-induced diarrhea and colitis: an overview
Zoghbi, M., Burk, K. J., Haroun, E., Saadé, M., & Carreras, M. T. C. (2024) · Supportive Care in Cancer · doi:10.1007/s00520-024-08889-2 · Cited by 31
Ando, H., Suzuki, K., & Yanagihara, T. (2021) · Biomedicines · doi:10.3390/biomedicines9101484 · Cited by 31
Mallio, C. A., Napolitano, A., Castiello, G., Giordano, F. M., D'Alessio, P., Iozzino, M., Sun, Y., Angeletti, S., Russano, M., Santini, D., et al. (2021) · Cancers · doi:10.3390/cancers13040652 · Cited by 30
Agarwal, S., & June, C. H. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0473 · Cited by 30
Nivolumab-Induced Large-Duct Cholangiopathy Treated with Ursodeoxycholic Acid and Tocilizumab
Reddy, C. A., Schneider, B. J., Brackett, L. M., & Tai, A. W. (2019) · Immunotherapy · doi:10.2217/imt-2019-0121 · Cited by 30
SARS-COV-2 infection and lung tumor microenvironment
Malkani, N., & Rashid, M. U. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06149-8 · Cited by 35
Checkpoint Inhibitors and Hepatotoxicity
Malnick, S. D. H., Abdullah, A., & Neuman, M. G. (2021) · Biomedicines · doi:10.3390/biomedicines9020101 · Cited by 31
Giommoni, E., Giorgione, R., Paderi, A., Pellegrini, E., Gambale, E., Marini, A., Antonuzzo, A., Marconcini, R., Roviello, G., Matucci‐Cerinic, M., et al. (2021) · Immuno · doi:10.3390/immuno1030017 · Cited by 30
Paraneoplastic Autoimmune Neurological Syndromes and the Role of Immune Checkpoint Inhibitors
Duong, S. L., & Prüss, H. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01184-0 · Cited by 29
Bjursten, S., Zhao, Z., Remawi, H. A., Studahl, M., Pandita, A., Simrén, J., Zetterberg, H., Lundell, A., Rudin, A., Ny, L., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2023.104955 · Cited by 28
IL-6 blockade in cancer patients treated with immune checkpoint blockade: A win-win strategy
Delyon, J., & Lebbé, C. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.04.010 · Cited by 28
Lin, X., Deng, H., Chu, T., Chen, L., Yang, Y., Qiu, G., Xie, X., Qin, Y., Liu, M., Xie, Z., et al. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-732 · Cited by 27
Elevated IL-6 and Tumor Necrosis Factor-α in Immune Checkpoint Inhibitor Myocarditis
Ali, A., Caldwell, R., Pina, G., Beinart, N. I., Jensen, G. L., Yusuf, S. W., Koutroumpakis, E., Hamzeh, I., Khalaf, S. Z., Iliescu, C., et al. (2024) · Diseases · doi:10.3390/diseases12050088 · Cited by 29
Brem, S. S. (2024) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2024.100859 · Cited by 32
Wachowska, M., Stachura, J., Tonecka, K., Fidyt, K., Braniewska, A., Sas, Z., Kotuła, I., Rygiel, T. P., Boon, L., Gołąb, J., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02528-5 · Cited by 27
Delire, B., Martin, E. D., Meunier, L., Larrey, D. G., & Horsmans, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.786174 · Cited by 28
Lin, X., Xie, M., Yao, J., Ma, X., Lin, Q., Zhang, X., Song, J., Bao, X., Zhang, X., Zhang, Y., et al. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1613 · Cited by 24
Dara, L., & Martin, E. D. (2025) · Liver International · doi:10.1111/liv.16198 · Cited by 27
Singh, B. P., Marshall, J. L., & He, A. R. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0304 · Cited by 26
Chatzidionysiou, K., Liapi, M., Tsakonas, G., Gunnarsson, I., & Catrina, A. (2020) · Clinical Rheumatology · doi:10.1007/s10067-020-05420-w · Cited by 24
Gómez-Puerta, J. A., Lobo-Prat, D., Pérez-García, C., Ponce, A., Frade‐Sosa, B., Arciniegas, A. M. M., Ojeda, F., Ruíz-Esquide, V., & Corominas, H. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.888377 · Cited by 23
Fuente, F. D. L., Belkhir, R., Henry, J., Nguyen, C. D., Pham, T., Germain, V., Gavand, P., Labadie, C., Brière, C., Lauret, A., et al. (2022) · RMD Open · doi:10.1136/rmdopen-2022-002612 · Cited by 23
Cheng, Y., Ling, F., Li, J., Chen, Y., Xu, M., Li, S., & Zhu, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1190850 · Cited by 23
Immune Pathogenesis of COVID-19 Intoxication: Storm or Silence?
Kiselevskiy, M., Shubina, I. Z., Chikileva, I. O., Ситдикова, С. М., Самойленко, И. В., Anisimova, N. Y., Киргизов, К. И., Сулейманова, А. М., Gorbunova, T., & Варфоломеева, С. Р. (2020) · Pharmaceuticals · doi:10.3390/ph13080166 · Cited by 22
Hu, X., Ren, J., Xue, Q., Luan, R., Ding, D., Tan, J., Su, X., & Yang, J. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5570 · Cited by 22
Overview of checkpoint inhibitor pneumonitis: incidence and associated risk factors
Shibata, Y., Murakami, S., & Kato, T. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1898584 · Cited by 21
Hu, X., Bukhari, S., Tymm, C. C., Adam, K. R., Lerrer, S., Henick, B. S., WINCHESTER, R. J., & Mor, A. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008482 · Cited by 20
Wahl, R. U., Leijs, M. M., Araujo, A., & Rübben, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062020 · Cited by 20
Cascella, M., Mauro, I., Blasio, E. D., Crispo, A., Gaudio, A. D., Bimonte, S., Cuomo, A., & Ascierto, P. A. (2020) · Medicina · doi:10.3390/medicina56080377 · Cited by 20
Kiss, I., Kühn, M., Hrušák, K., & Büchler, T. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100474 · Cited by 22
Wang, W., Wang, Q., Xu, C., Li, Z., Song, Z., Zhang, Y., Cai, X., Zhang, S., Lian, B., Li, W., et al. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14693 · Cited by 20
GAUDIO, A. D., Vincenzo, F. D., Petito, V., Giustiniani, M. C., Gasbarrini, A., Scaldaferri, F., & Lopetuso, L. R. (2023) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izad229 · Cited by 20
Naidoo, J., Reuss, J. E., Suresh, K. S., Feller-Kopman, D. J., Forde, P. M., Steinke, S. M., Rock, C., Johnson, D. B., Nishino, M., & Brahmer, J. R. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000984 · Cited by 19
Wang, X., Wang, J., Wang, Q., Ding, G., Huang, Y., & Feng, Y. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189536 · Cited by 19
Chan, K. K., & Bass, A. R. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s282600 · Cited by 21
Ali, S. B., Vembar, P., Sukumaran, S., Gunawardane, D. N., Hughes, T. L., & Smith, A. (2023) · Immunotherapy · doi:10.2217/imt-2023-0085 · Cited by 18
Chen, Y., Luo, Y., Liu, Y., Luo, D., & Liu, A. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03899-9 · Cited by 18
Lin, A., Zheng, K., Jiang, A., Huang, X., Wang, Q., Hajdú, A., Li, Z., Zhang, J., & Luo, P. (2025) · Med Research · doi:10.1002/mdr2.70019 · Cited by 19
Li, X., Lv, F., Wang, Y., & Du, Z. (2022) · BMC Pulmonary Medicine · doi:10.1186/s12890-022-02127-3 · Cited by 17
Evaluation of the Tocilizumab therapy in human cancers: Latest evidence and clinical potential
Ghasemi, K., & Ghasemi, K. (2022) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13781 · Cited by 17
Managing Select Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitors
Cheema, P. K., Iafolla, M. A. J., Abdel-Qadir, H. M., Bellini, A. B., Chatur, N., Chandok, N., Comondore, V. R., Cunningham, M. E., Halperin, I. J., Hu, A. C., et al. (2024) · Current Oncology · doi:10.3390/curroncol31100473 · Cited by 18
Sun, Y., Shao, C., Li, S., Xu, Y., Xu, K. L., Zhang, Y., Huang, H. F., Wang, M., & Xu, Z. (2020) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13380 · Cited by 16
Clinical management of checkpoint inhibitor pneumonitis: Focus, challenges, and future directions
Xu, Y., Chen, R., Pan, R., Gao, X., Huang, H. F., & Wang, M. (2025) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2024.12.001 · Cited by 17
Wang, P., Zhang, Z., Zhang, S., Xing, Q., Zhao, Z., Lin, Q., Shen, L., Xia, Z., Li, F., & Zhu, B. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04696-0 · Cited by 17
Considerations and Approaches for Cancer Immunotherapy in the Aging Host
Ontiveros, C. O., Murray, C. E., Crossland, G. E., & Curiel, T. J. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0121 · Cited by 16
Malvaso, A., Giglio, P., Diamanti, L., Gastaldi, M., Vegezzi, E., Pace, A., Bini, P., & Marchioni, E. (2024) · Brain Sciences · doi:10.3390/brainsci14080764 · Cited by 17
Shannon, V. R. (2020) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000689 · Cited by 16
Mechanisms of dermatological toxicities to immune checkpoint inhibitor cancer therapies
Seervai, R. N. H., Sinha, A., & Kulkarni, R. P. (2022) · Clinical and Experimental Dermatology · doi:10.1111/ced.15332 · Cited by 16
Marar, R. I., Prathivadhi-Bhayankaram, S. V., & Krishnan, M. (2022) · Journal of Hematology · doi:10.14740/jh1033 · Cited by 15
Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors
Zhou, Y., & Li, H. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1227049 · Cited by 15
Tan, S., Chang, Q., Zeng, H., Wei, Q., Huang, Q. M., Pu, X., Li, W., Li, Y., & Tian, P. (2024) · Cardiovascular Toxicology · doi:10.1007/s12012-024-09918-6 · Cited by 16
Guerini, A. E., Borghetti, P., Filippi, A. R., Bonù, M. L., Tomasini, D., Greco, D., Imbrescia, J., Volpi, G., Triggiani, L., Borghesi, A., et al. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.05.027 · Cited by 15
Desmedt, V., Jauregui-Amezaga, A., Fierens, L., Aspeslagh, S., Dekervel, J., Wauters, E., Peeters, M., Sabino, J., Crapé, L., Somers, M. J. G., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.03.025 · Cited by 14
Lasagna, A., & Sacchi, P. (2024) · Cancers · doi:10.3390/cancers16040795 · Cited by 17
Syc‐Mazurek, S. B., Zhao-Fleming, H. H., Guo, Y. X., Tisavipat, N., Chen, J. J.-W., Ζεκερίδου, Α., Kournoutas, I. A., Orme, J. J., Block, M. S., Lucchinetti, C. F., et al. (2024) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200249 · Cited by 14
Cancer therapy-related interstitial lung disease
Zhou, C., Deng, H., Yang, Y., Wang, F., Lin, X., Liu, M., Xie, X., Luan, T., & Zhong, N. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003149 · Cited by 15
Checkpoint inhibitor-associated autoimmunity
Ladak, K., & Bass, A. R. (2018) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2019.03.009 · Cited by 14
Hepatobiliary and Pancreatic Adverse Events
Zhang, H. C., Wang, L. S., & Miller, E. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-79308-1_13 · Cited by 14
Wu, Y., Yu, S., & Qiao, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.990445 · Cited by 14
Atezolizumab-associated Dermatomyositis in Advanced Small-cell Lung Carcinoma
Yamaguchi, Y., Aso, M., Nagasawa, H., & Wada, M. (2021) · Internal Medicine · doi:10.2169/internalmedicine.6917-20 · Cited by 14
Li, S., Geng, Z., Hong, S., Zhang, J., Yang, Y., Qin, W. D., Zhang, X., Zhuang, X., Huo, R., Han, S., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1656063 · Cited by 15
Hu, X., Wang, L., Shang, B., Wang, J., Sun, J., Liang, B., Su, L., You, W., & Jiang, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1094414 · Cited by 13
Miao, K., & Zhang, L. (2023) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2023.08.002 · Cited by 13
A Potential New Use for Tocilizumab: Refractory Checkpoint Inhibitor Hepatitis
Lyles, L. A., Farmer, R., & Abougergi, M. S. (2023) · ACG Case Reports Journal · doi:10.14309/crj.0000000000001162 · Cited by 13
Bonomi, M., Maltese, M., Brighenti, M., Muri, M., & Passalacqua, R. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.08.002 · Cited by 13
Sørensen, A. S., Andersen, M. N., Juul‐Madsen, K., Broksø, A. D., Skejø, C., Schmidt, H., Vorup‐Jensen, T., & Kragstrup, T. W. (2022) · Arthritis Research & Therapy · doi:10.1186/s13075-022-02737-6 · Cited by 12
COVID-19 and Lung Cancer: A Comprehensive Overview from Outbreak to Recovery
Bungaro, M., Passiglia, F., & Scagliotti, G. (2022) · Biomedicines · doi:10.3390/biomedicines10040776 · Cited by 9
Glehr, G., Riquelme, P., Zhou, J. Y., Cordero, L., Schilling, H., Kapinsky, M., Schlitt, H. J., Geissler, E. K., Burkhardt, R., Schmidt, B., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1011040 · Cited by 14
Pundole, X., Sarangdhar, M., & Suarez-Almazor, M. E. (2019) · Journal of Immunotherapy and Precision Oncology · doi:10.4103/jipo.jipo_12_19 · Cited by 13
Burri, E., Mangana, J., Cheng, P. F., Schneider, A., Weber, A., Dummer, R., & Ramelyte, E. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008074 · Cited by 15
Wong, H. S.-C., Guo, C., Lin, G.-H., Lee, K.-Y., Okada, Y., & Chang, W. (2021) · Genomics · doi:10.1016/j.ygeno.2020.12.041 · Cited by 12
Insomnia in patients treated with checkpoint inhibitors for cancer: A meta-analysis
Kišš, I., Kuhn, M., Hrušák, K., Buchler, B., Boublíková, L., & Büchler, T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.946307 · Cited by 12
Immunotherapeutic Strategies in the Management of Osteosarcoma
Supra, R., & Agrawal, D. K. (2023) · Journal of Orthopaedics and Sports Medicine · doi:10.26502/josm.511500076 · Cited by 11
Jono, M., Kinehara, Y., Utsu, Y., Tamura, Y., Koseto, M., Murakami, T., Uota, A., Ninomiya, R., Komo, S., Sumitani, S., et al. (2019) · Internal Medicine · doi:10.2169/internalmedicine.3782-19 · Cited by 12
Tacrolimus for the Management of Delayed Onset and Treatment-Refractory Immune-Related Hepatitis
Ea, V., Ngu, N. L. Y., Kua, H. W., & Mishra, G. (2023) · ACG Case Reports Journal · doi:10.14309/crj.0000000000001007 · Cited by 11
Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors
Chen, Y. H., Kovács, T., Ferdinandy, P., & Varga, Z. V. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16405 · Cited by 12
Managing Immune Checkpoint Inhibitor Pneumonitis in the ICU
Montemayor, K., Ghanbar, M., Koch, A. L., Suresh, K. S., & Stephens, R. S. (2024) · CHEST Critical Care · doi:10.1016/j.chstcc.2024.100126 · Cited by 11
Immune checkpoint inhibitor-related pneumonitis: From guidelines to the front lines
Karayama, M. (2025) · Respiratory Investigation · doi:10.1016/j.resinv.2025.07.023 · Cited by 13
Reid, P. D., Sandigursky, S., Song, J., Lopez-Olivo, M. A., Safa, H., Cytryn, S. L., Efuni, E., Buni, M., Pavlick, A. C., Krogsgaard, M., et al. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2261264 · Cited by 11
Pharmacological Treatments Available for Immune-Checkpoint-Inhibitor-Induced Colitis
Ohwada, S., Ishigami, K., Akutsu, N., & Nakase, H. (2022) · Biomedicines · doi:10.3390/biomedicines10061334 · Cited by 11
Current landscape and tailored management of immune-related adverse events
Liu, W., Luo, Z., Liu, Y., & Sun, B. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1078338 · Cited by 10
Immune-Related Adverse Events (irAEs): Implications for Immune Checkpoint Inhibitor Therapy
Zhou, N., Velez, M. A., Owen, D. H., & Lisberg, A. E. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.7640 · Cited by 10
Pulmonary Toxicities of Immunotherapy
Altan, M., Zhong, L., Shannon, V. R., & Sheshadri, A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-79308-1_14 · Cited by 10
Cytokine storm induced by a PD1 inhibitor in a renal transplant patient
Bello, A. D., Zakaroff, A. G., Meyer, N., Delas, A., Faguer, S., Kamar, N., & Bellière, J. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16589 · Cited by 10
Immune checkpoint inhibitors: From friend to foe
Rajak, P. (2025) · Toxicology Reports · doi:10.1016/j.toxrep.2025.102033 · Cited by 9
Ma, H., Zhang, S., Jiao, P., Ding, H., Wang, F., Zhao, Y., Wu, J., & Guo, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1553882 · Cited by 9
Metadata
- Authors
- Stroud, C. R., Hegde, A., Cherry, C., Naqash, A. R., Sharma, N., Addepalli, S., Cherukuri, S., Parent, T., Hardin, J., & Walker, P.
- Affiliations
- East Carolina University (US)
- Corresponding author
- Hegde, Aparna
- Venue
- Journal of Oncology Pharmacy Practice
- Publisher
- SAGE Publications
- Published
- 2017-12-05
- Volume
- 25
- Issue
- 3
- Pages
- 551-557
- ISSN
- 1078-1552 (ISSN-L)
- 1477-092X
- OpenAlex
- W2771433910
- Cited by
- 331
- References
- 26
- Citations by year
- 2026: 25 · 2025: 28 · 2024: 43 · 2023: 45 · 2022: 55 · 2021: 46 · 2020: 58 · 2019: 22 · 2018: 7 · 2017: 1
- FWCI
- 10.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Oncology Pharmacy Practice (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tocilizumab, immune checkpoint inhibitors, immune-related adverse events, nivolumab, IL-6 receptor inhibitor, pneumonitis, serum sickness, C-reactive protein, lung cancer, hypophysitis, colitis, cerebritis, hypotension, hypoxemia
- MeSH terms
- Nivolumab, Adrenal Cortex Hormones, Adult, Aged, Aged, 80 and over, Female, Humans, Lung Neoplasms, Male, Middle Aged, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
